Sensata Technologies Announces Live Webcast of Presentation at the Citi Global Technology Conference
Sep 05, 2017 11:03 am UTC| Business
HENGELO, the Netherlands, Sept. 05, 2017 -- Sensata Technologies (NYSE:ST) announced today that Martha Sullivan, President and CEO, will speak to the investment community at the Citi Global Technology Conference on...
$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
Sep 05, 2017 11:01 am UTC| Business
With funding now in place Pluristem plans to launch a multinational Phase III in U.S. and EuropeTotal of $16.7 Million (15 million Euro) in non-dilutive funding have been awarded from the Horizon 2020 program to fund...
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
Sep 05, 2017 11:01 am UTC| Business
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the fourth in the broader...
Sep 05, 2017 11:01 am UTC| Business
OXFORD, United Kingdom, Sept. 05, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile...
Sabina Gold & Silver Discovers New High Grade Mineral Zone Within Llama Gold Trend
Sep 05, 2017 11:01 am UTC| Business
VANCOUVER, British Columbia, Sept. 05, 2017 -- Sabina Gold Silver Corp. (“Sabina”) or (the “Company”) (TSX:SBB) is pleased to announce the first results from the summer exploration diamond drilling program at its 100%...
Sep 05, 2017 11:01 am UTC| Business
WINNEMUCCA, Nev., Sept. 05, 2017 -- Paramount Gold Nevada Corp. (NYSE American:PZG) (“Paramount”) announced today that it has met a significant milestone by filing its mine Plan of Operation (“POO”) with the Federal...
Sep 05, 2017 11:01 am UTC| Business
Study met primary endpoint of culture conversion (p 0.0001)Positive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection Company plans to pursue...